MYLAN-TERAZOSIN TABLET

País: Canadá

Idioma: inglés

Fuente: Health Canada

Ingredientes activos:

TERAZOSIN HYDROCHLORIDE

Disponible desde:

MYLAN PHARMACEUTICALS ULC

Código ATC:

G04CA03

Designación común internacional (DCI):

TERAZOSIN

Dosis:

1MG

formulario farmacéutico:

TABLET

Composición:

TERAZOSIN HYDROCHLORIDE 1MG

Vía de administración:

ORAL

Unidades en paquete:

100

tipo de receta:

Prescription

Área terapéutica:

ALPHA-ADRENERGIC BLOCKING AGENTS

Resumen del producto:

Active ingredient group (AIG) number: 0121210003; AHFS:

Estado de Autorización:

CANCELLED POST MARKET

Fecha de autorización:

2016-06-28

Ficha técnica

_ _
_ _
_Page 1 of 39_
PRODUCT MONOGRAPH
PR
MYLAN-TERAZOSIN
Terazosin Hydrochloride Tablets
1 mg, 2 mg 5 mg and 10 mg
Antihypertensive Agent
Symptomatic Treatment of Benign Prostatic Hyperplasia (BPH)
Mylan Pharmaceuticals ULC
85 Advance Road
Etobicoke, ON
M8Z 2S6
Date of Revision:
November 17, 2014
Submission Control No: 179465
_ _
_ _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
.......................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
..................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
10
DRUG INTERACTIONS
.................................................................................................
13
DOSAGE AND ADMINISTRATION
.............................................................................
14
OVERDOSAGE
...............................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................... 16
STORAGE AND STABILITY
.........................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................ 19
PART II: SCIENTIFIC INFORMATION
...............................................................................
20
PHARMACEUTICAL INFORMATION
.........................................................................
20
CLINICAL TRIALS
.........................................................................................................
21
DETAILED PHARMACOLOGY
.